E Galanis

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma
    Evanthia Galanis
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 20:1998-2003. 2012
  2. ncbi Attenuated oncolytic measles virus strains as cancer therapeutics
    P Msaouel
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Pharm Biotechnol 13:1732-41. 2012
  3. ncbi Phase 2 trial design in neuro-oncology revisited: a report from the RANO group
    Evanthia Galanis
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet Oncol 13:e196-204. 2012
  4. ncbi Vorinostat in solid and hematologic malignancies
    David Siegel
    Hackensack University Medical Center, Hackensack, NJ, USA
    J Hematol Oncol 2:31. 2009
  5. ncbi Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience
    E Galanis
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 17:3313-23. 1999
  6. ncbi Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study
    Evanthia Galanis
    Mayo Clinic, Gonda 10 141, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 27:2052-8. 2009
  7. ncbi Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma
    Evanthia Galanis
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 101:2557-66. 2004
  8. ncbi Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer
    Evanthia Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 16:979-84. 2008
  9. ncbi Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study
    Evanthia Galanis
    Mayo Clinic and Mayo Foundation, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:5294-304. 2005
  10. ncbi Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial
    Evanthia Galanis
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Invest New Drugs 23:495-503. 2005

Detail Information

Publications59

  1. ncbi Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma
    Evanthia Galanis
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 20:1998-2003. 2012
    ..Based on preclinical data showing synergy with taxane and platinum compounds, a phase II combination trial in metastatic melanoma patients is ongoing...
  2. ncbi Attenuated oncolytic measles virus strains as cancer therapeutics
    P Msaouel
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Pharm Biotechnol 13:1732-41. 2012
    ....
  3. ncbi Phase 2 trial design in neuro-oncology revisited: a report from the RANO group
    Evanthia Galanis
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet Oncol 13:e196-204. 2012
    ..The rational incorporation of these designs, as determined by the specific clinical setting and the trial's endpoints or goals, has the potential to substantially advance new drug development in neuro-oncology...
  4. ncbi Vorinostat in solid and hematologic malignancies
    David Siegel
    Hackensack University Medical Center, Hackensack, NJ, USA
    J Hematol Oncol 2:31. 2009
    ....
  5. ncbi Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience
    E Galanis
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 17:3313-23. 1999
    ....
  6. ncbi Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study
    Evanthia Galanis
    Mayo Clinic, Gonda 10 141, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 27:2052-8. 2009
    ..Vorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM)...
  7. ncbi Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma
    Evanthia Galanis
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 101:2557-66. 2004
    ..In the current study, the authors investigated the safety and efficacy of in situ vaccination with Leuvectin in patients with metastatic renal cell carcinoma...
  8. ncbi Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer
    Evanthia Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 16:979-84. 2008
    ..5 months from treatment initiation. Rexin-G is well tolerated in doses up to 6 x 10(11) CFU in patients with recurrent pancreatic cancer, but there was no evidence of clinical antitumor activity...
  9. ncbi Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study
    Evanthia Galanis
    Mayo Clinic and Mayo Foundation, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:5294-304. 2005
    ..Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma multiforme (GBM)...
  10. ncbi Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial
    Evanthia Galanis
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Invest New Drugs 23:495-503. 2005
    ....
  11. ncbi Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods
    Evanthia Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Neuro Oncol 8:156-65. 2006
    ....
  12. ncbi Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer
    Evanthia Galanis
    Division of Medical Oncology, Department of Molecular Medicine, Mayo Clinic, Gonda 10 141, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Res 70:875-82. 2010
    ..Our findings indicate that i.p. administration of MV-CEA is well tolerated and results in dose-dependent biological activity in a cohort of heavily pretreated recurrent ovarian cancer patients...
  13. ncbi Therapeutic potential of oncolytic measles virus: promises and challenges
    E Galanis
    Departments of Oncology and Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Clin Pharmacol Ther 88:620-5. 2010
    ..In this article, we review potential applications and challenges associated with use of MV strains as cancer therapeutics...
  14. ncbi Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments
    Evanthia Galanis
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 13:42-9. 2011
    ..In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients...
  15. ncbi Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study
    Bret B Friday
    Essentia Health Duluth Clinic Cancer Center, Duluth, Minnesota, USA
    Neuro Oncol 14:215-21. 2012
    ..On the basis of the results of this phase II study, further evaluation of the vorinostat-bortezomib combination in GBM patients in this dose and schedule is not recommended...
  16. ncbi Technology evaluation: Allovectin-7, Vical
    Evanthia Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Curr Opin Mol Ther 4:80-7. 2002
    ..Trials of Allovectin-7 as an adjuvant treatment in earlier stages of disease evolution are planned...
  17. ncbi Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd)
    E Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Oncol 12:701-7. 2001
    ..Evidence of potential antitumor activity was observed: 1 patient (with colon cancer) had a partial response while 15 others had stable disease...
  18. ncbi Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors
    E Galanis
    Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Crit Rev Oncol Hematol 38:177-92. 2001
    ..Early clinical results and limitations in the application of these vectors are discussed...
  19. ncbi Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas
    E Galanis
    Medical Oncology and Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Hum Gene Ther 12:811-21. 2001
    ..In summary, the viral fusogenic membrane glycoproteins (GALV and the MV-F + MV-H combination) are potent therapeutic transgenes with potential utility in the gene therapy of gliomas...
  20. ncbi Efficacy of neuroradiological imaging, neurological examination, and symptom status in follow-up assessment of patients with high-grade gliomas
    E Galanis
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Neurosurg 93:201-7. 2000
    ..The validity of this practice and its impact on the welfare of patients with high-grade gliomas has not been adequately assessed. The purpose of this study is to provide such an assessment...
  21. ncbi Chemotherapy of brain tumors
    E Galanis
    Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Curr Opin Neurol 13:619-25. 2000
    ..Gliomas, the most common malignant brain tumors, represent the main focus of the review; chemotherapeutic options for supratentorial, brain stem, and optic track gliomas are discussed...
  22. ncbi New adjuvant therapy for colon cancer: justified hope or commercial hype
    E Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Surg Oncol Clin N Am 9:813-23; discussion 825-6. 2000
    ..Future directions in the adjuvant treatment of colon cancer include incorporation of newer agents such as irinotecan, oxaliplatin, oral fluorinated pyrimidines, and immunotherapeutic approaches...
  23. ncbi Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas
    Georgia Paraskevakou
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Mol Ther 15:677-86. 2007
    ....
  24. ncbi Heat shock protein inhibitors increase the efficacy of measles virotherapy
    C Liu
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Gene Ther 15:1024-34. 2008
    ..The enhanced cytopathic effect resulting from measles virus/GA combination supports the translational potential of this approach in the treatment of cancer...
  25. ncbi High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system
    Paula Gill
    Department of Oncology, Franciscan Skemp Healthcare Mayo Health Systems, LaCrosse, Wisconsin, USA
    Cancer 112:1805-11. 2008
    ..The purpose of the current study was to evaluate adult patients with embryonal CNS tumors who were treated with HDC with ASCT and compare their outcomes with those of patients who received conventional-dose chemotherapy...
  26. ncbi Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas
    Rae Myers
    Molecular Medicine Program, Mayo Clinic, Rochester, MN 55905, USA
    Hum Gene Ther 19:690-8. 2008
    ..Our results support the safety of CNS administration of MV-CEA in glioma patients. A clinical trial of intratumoral and resection cavity administration of MV-CEA in patients with recurrent glioblastoma multiforme is currently ongoing...
  27. ncbi Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity
    Cory Allen
    Molecular Medicine Department, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Mol Ther 16:1556-64. 2008
    ..Strains of measles virus retargeted against the glioma-specific IL-13Ralpha2 receptor have comparable therapeutic efficacy, and improved specificity as compared with the unmodified measles virus strain MV-GFP in vitro and in vivo...
  28. ncbi PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel
    Lin Yang
    Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Clin Cancer Res 14:3993-4001. 2008
    ....
  29. ncbi Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex
    G A Daniels
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Opin Mol Ther 3:70-6. 2001
    ..Clinical trials employing higher doses of the plasmid in renal cell carcinoma patients with limited disease are ongoing...
  30. ncbi Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction
    K J Johnson
    Molecular Medicine Program, Mayo Clinic, Rochester, MN, USA
    Gene Ther 10:725-32. 2003
    ..Given the high frequency of MMP overexpression in gliomas, this represents a promising targeting strategy...
  31. ncbi Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas
    E Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Gene Ther 12:437-45. 2005
    ..There was evidence of antitumor activity in one out of six patients. Further investigation of this approach in patients with recurrent sarcomas is warranted...
  32. ncbi Intraperitoneal therapy of ovarian cancer using an engineered measles virus
    Kah Whye Peng
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 62:4656-62. 2002
    ..Trackable recombinant measles viruses warrant further investigation for therapy of ovarian cancer...
  33. ncbi Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme
    Caterina Giannini
    Departments of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Neuro Oncol 7:164-76. 2005
    ..The fact that such studies were carried out by using an invasive tumor model in an anatomically appropriate context should ensure a rigorous preclinical assessment of agent efficacy...
  34. ncbi A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer
    Cari J McDonald
    Molecular Medicine Program, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:177-84. 2006
    ..Trackable measles virus derivatives merit further exploration in breast cancer treatment...
  35. ncbi Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results
    Marta Santisteban
    Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    J Neurooncol 92:165-75. 2009
    ....
  36. ncbi Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts
    A B D'Assoro
    Department of Biochemistry and Molecular Biology, Tumor Biology Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Oncogene 27:3901-11. 2008
    ..Taken together, these observations indicate that abrogation of p53 function and consequent deregulation of the G1/S cell cycle transition leads to centrosome amplification responsible for breast cancer progression...
  37. ncbi Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors
    Matthew P Goetz
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 21:3761-9. 2003
    ..Additionally, we investigated the effect of CPT-11 on oxaliplatin pharmacokinetics...
  38. ncbi Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Nat Rev Clin Oncol 6:507-18. 2009
    ..Nonetheless, anti-VEGF therapy has enhanced the arsenal of anticancer therapies and has provided new insights into the biology of malignancy...
  39. ncbi Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice
    Kah Whye Peng
    Molecular Medicine Program, Guggenheim 18, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Hum Gene Ther 14:1565-77. 2003
    ....
  40. ncbi Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas
    Cory Allen
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Gene Med 6:1216-27. 2004
    ..Given the high frequency of MMP overexpression in gliomas, AdM40 represents a potentially promising agent in the gene therapy of these tumors...
  41. ncbi Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM
    Kurt A Jaeckle
    Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    J Neurooncol 99:73-80. 2010
    ..This regimen was not significantly active and radiosensitization was not observed. Non-EIAC patients with UGT1A1*28 variant alleles appear particularly sensitive to toxicity from irinotecan...
  42. ncbi Engineered measles virus as a novel oncolytic therapy against prostate cancer
    Pavlos Msaouel
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Prostate 69:82-91. 2009
    ..In this study, we investigated the antitumor potential of recombinant MV-Edm derivatives as novel oncolytic agents against prostate cancer...
  43. ncbi Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice
    Brian A Neff
    Department of Otolaryngology Head and Neck Surgery, Mayo Clinic School of Medicine, Rochester, Minnesota 55905, USA
    Otol Neurotol 30:105-11. 2009
    ..Intracranial vestibular schwannoma xenografts can be successfully established and followed with bioluminescent imaging (BLI)...
  44. ncbi Converting tumor-specific markers into reporters of oncolytic virus infection
    Ianko D Iankov
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Mol Ther 17:1395-403. 2009
    ..This is the first report of a gene therapy vector engineered to discriminate between infection in malignant and normal cells by molecular modification of a tumor-specific protein...
  45. ncbi Malignant melanoma in the 21st century: the emerging molecular landscape
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 83:825-46. 2008
    ..We review the emerging molecular landscape of melanoma and its implications for better management of patients with melanoma...
  46. ncbi Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme
    Chunsheng Liu
    Molecular Medicine Program, Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 13:7155-65. 2007
    ..Radiation therapy (RT) represents one of the mainstays of glioma treatment. Here we tested the hypothesis that the combination of RT with MV-CEA would have synergistic activity against gliomas...
  47. ncbi Phase II trial of gemcitabine in advanced sarcomas
    Scott Okuno
    Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer 94:3225-9. 2002
    ..Gemcitabine, a nucleoside antimetabolite, is an analog of deoxycytidine that has shown antitumor activity in several tumors. The aim of the current study was to determine the clinical activity of gemcitabine in patients with sarcomas...
  48. ncbi Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates
    Lijo Simpson
    Mayo Clinic, Department of Oncology, 200 1st Str SW, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 6:1593-607. 2006
    ....
  49. ncbi Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity
    Cory Allen
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 66:11840-50. 2006
    ....
  50. ncbi Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model
    Emily K Mader
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 15:7246-55. 2009
    ..Hence, we hypothesized that measles virotherapy of ovarian cancer in measles-immune mice might be superior if MV-infected mesenchymal stem cell (MSC) carriers are used...
  51. ncbi Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model
    Ianko D Iankov
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res Treat 122:745-54. 2010
    ..This is the first demonstration of the therapeutic potential of oncolytic virotherapy against malignant pleural effusions in a pre-clinical model of advanced breast cancer...
  52. ncbi Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter
    Pavlos Msaouel
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 17:2041-8. 2009
    ..The NIS transgene allows viral localization and monitoring by noninvasive imaging which can facilitate dose optimization in a clinical setting...
  53. ncbi Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview
    Pavlos Msaouel
    Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Curr Opin Mol Ther 11:43-53. 2009
    ..The information obtained from these ongoing trials will guide the future clinical application and further development of MV strains as anticancer agents...
  54. ncbi Oncolytic measles virus strains in the treatment of gliomas
    Cory Allen
    Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA
    Expert Opin Biol Ther 8:213-20. 2008
    ..Recurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy...
  55. ncbi Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas
    Mateusz Opyrchal
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Methods Mol Biol 542:705-17. 2009
    ..We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas...
  56. ncbi Vertebra plana caused by primary Ewing sarcoma: case report and review of the literature
    Panayiotis J Papagelopoulos
    Department of Orthopedic Surgery, Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, U.S.A
    J Spinal Disord Tech 15:252-7. 2002
    ..Progressive neurologic symptoms required surgical excision of the lesion and decompression. Histopathologic examination of the surgical specimen confirmed the diagnosis of Ewing sarcoma...
  57. ncbi Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer
    Oday Hamid
    Pfizer Global Research and Development, 2800 Plymouth Rd, Ann Arbor, MI 48105, USA
    J Clin Oncol 21:1498-504. 2003
    ..To evaluate the antitumor activity, safety, immune response, and replication of CI-1042 (ONYX-015), an E1B 55-kd gene-deleted replication-selective adenovirus, administered intravenously to patients with metastatic colorectal cancer..
  58. ncbi Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
    Jann N Sarkaria
    Department of Neurological Surgery, University of California, San Francisco, Room HSW 792, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Mol Cancer Ther 6:1167-74. 2007
    ....
  59. ncbi Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
    Ta Chiang Liu
    Jennerex Biotherapeutics, One Market Street, Spear Tower, Suite 2260, San Francisco, CA 94105, USA
    Nat Clin Pract Oncol 4:101-17. 2007
    ..Systemic safety and efficiacy has been clearly demonstrated with some virotherapeutics. The implications of these data for future virotherapy development are discussed...